

# INCYTE PORTFOLIO:

## Targeted therapy & immunotherapy

### Targeted Therapy

	CLINICAL PROOF OF CONCEPT	PIVOTAL	MARKETED
Jakafi® (ruxolitinib) <sup>1</sup> - JAK1/JAK2	Myelofibrosis <sup>2</sup> , polycythemia vera <sup>3</sup> , acute graft-versus-host disease (GVHD) <sup>4</sup>		U.S.
Pemazyre™ (pemigatinib) - FGFR1/2/3	Cholangiocarcinoma <sup>5</sup>		U.S.
Iclusig® (ponatinib) <sup>6</sup> - BCR-ABL	Chronic myeloid leukemia <sup>7</sup> , Ph+ acute lymphoblastic leukemia <sup>8</sup>		EUROPE
ruxolitinib <sup>9</sup> - JAK1/JAK2	Chronic GVHD, COVID-19 associated cytokine storm		
ruxolitinib + parsaclisib - JAK1/JAK2, PI3Kδ	Myelofibrosis		
itacitinib - JAK1	Chronic GVHD		
tafasitamab <sup>10</sup> - CD19	Diffuse large B-cell lymphoma		
tafasitamab <sup>10</sup> - CD19	Chronic lymphocytic leukemia		
pemigatinib - FGFR1/2/3	Bladder cancer, solid tumors, 8p11 myeloproliferative neoplasms		
parsaclisib - PI3Kδ	Follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma		
INCB57643 - BET	Myelofibrosis		
INCB00928 - ALK2	Myelofibrosis		
INCB53914 - PIM	Advanced malignancies		
INCB59872 - LSD1	Acute myeloid leukemia		

### Immuno-Oncology

	CLINICAL PROOF OF CONCEPT	PIVOTAL	MARKETED
retifanlimab <sup>11</sup> - PD-1	Non-small cell lung cancer (NSCLC)		
retifanlimab <sup>11</sup> - PD-1	Solid tumors (anal, MSI-H endometrial and Merkel cell)		
INCB86550 - PD-L1	Solid tumors		
MCLA-145 <sup>12</sup> - PD-L1xCD137	Solid tumors		
epacadostat - IDO1	Multiple tumor types		
INCB01158 <sup>13</sup> - ARG	Multiple tumor types		
INCAGN1876 <sup>14</sup> - GITR	Solid tumors		
INCAGN1949 <sup>14</sup> - OX40	Solid tumors		
INCAGN2390 <sup>14</sup> - TIM-3	Solid tumors		
INCAGN2385 <sup>14</sup> - LAG-3	Multiple tumor types		
INCB81776 - AXL/MER	Multiple tumor types		

### Inflammation/Autoimmunity

	CLINICAL PROOF OF CONCEPT	PIVOTAL	MARKETED
ruxolitinib cream - JAK1/JAK2	Atopic dermatitis, vitiligo		
INCB00928 - ALK2	Fibrodysplasia ossificans progressiva		
INCB54707 - JAK1	Hidradenitis suppurativa		
parsaclisib - PI3Kδ	Autoimmune hemolytic anemia		

### Partnered

	CLINICAL PROOF OF CONCEPT	PIVOTAL	MARKETED
Olumiant® (baricitinib) <sup>15</sup> - JAK1/JAK2	Rheumatoid arthritis		
Tabrecta™ (capmatinib) <sup>16</sup> - MET	NSCLC with METex14		U.S.
baricitinib <sup>15</sup> - JAK1/JAK2	Atopic dermatitis, systemic lupus erythematosus, alopecia areata		
capmatinib <sup>16</sup> - MET	Liver cancer		

Updated as of May 8, 2020

1. Jakafi marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis ex-U.S. 2. Adults with intermediate or high-risk myelofibrosis 3. Adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. Adults and pediatric patients 12 years and older with steroid-refractory acute GVHD 5. Adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test 6. European rights to Iclusig licensed from ARIAD 7. Adults with chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation 8. Adults with Ph+ ALL who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation 9. Certain development programs conducted in collaboration with Novartis 10. In collaboration with MorphoSys 11. In collaboration with MacroGenics 12. In collaboration with Merus 13. Co-development with Calithera 14. Discovery collaboration with Agenus 15. Worldwide rights to baricitinib licensed to Lilly; approved in multiple territories globally for certain patients with moderate to severe rheumatoid arthritis 16. Worldwide rights to capmatinib licensed to Novartis; approved in the U.S. for adults with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.

